Aram Andrew Mangasarian
Chief Executive Officer at TME PHARMA N.V.
Profile
Aram Andrew Mangasarian is currently the Chief Executive Officer & Non-Executive Director at NOXXON Pharma AG since 2015.
He is also the Chief Executive Officer at TME Pharma NV since 2015.
Additionally, he holds the position of Director at NOXXON Pharma NV Niederlassung Deutschland.
Previously, he worked as a Director at Caerus Consulting AS.
From 2020 to 2023, he served as an Independent Director at Isofol Medical AB.
He was the Vice President-Development Affairs at Novexel SA from 2005 to 2012.
He also worked as a Manager at Exonhit from 2000 to 2012 and as the Vice President-Business Development at Eurobio-Scientific SA. Dr. Mangasarian completed his undergraduate degree at the University of Wisconsin.
He holds an MBA from INSEAD and a doctorate from the University of California San Diego.
Aram Andrew Mangasarian active positions
Companies | Position | Start |
---|---|---|
TME PHARMA N.V. | Chief Executive Officer | 2010-04-30 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Chief Executive Officer | 2010-04-30 |
NOXXON Pharma NV Niederlassung Deutschland
NOXXON Pharma NV Niederlassung Deutschland BiotechnologyHealth Technology NOXXON Pharma NV Niederlassung Deutschland operates as a German biotechnology company. The private company is based in Berlin, Germany. | Director/Board Member | - |
Former positions of Aram Andrew Mangasarian
Companies | Position | End |
---|---|---|
ISOFOL MEDICAL AB | Director/Board Member | 2023-01-31 |
EUROBIO SCIENTIFIC | Corporate Officer/Principal | - |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Corporate Officer/Principal | - |
Caerus Consulting AS
Caerus Consulting AS Pharmaceuticals: MajorHealth Technology Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway. | Director/Board Member | - |
Novexel SA
Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | Corporate Officer/Principal | - |
Training of Aram Andrew Mangasarian
University of Wisconsin | Undergraduate Degree |
INSEAD | Masters Business Admin |
University of California San Diego | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
ISOFOL MEDICAL AB | Health Technology |
EUROBIO SCIENTIFIC | Health Technology |
TME PHARMA N.V. | Health Technology |
Private companies | 5 |
---|---|
Novexel SA
Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | Health Technology |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Health Technology |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Health Technology |
Caerus Consulting AS
Caerus Consulting AS Pharmaceuticals: MajorHealth Technology Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway. | Health Technology |
NOXXON Pharma NV Niederlassung Deutschland
NOXXON Pharma NV Niederlassung Deutschland BiotechnologyHealth Technology NOXXON Pharma NV Niederlassung Deutschland operates as a German biotechnology company. The private company is based in Berlin, Germany. | Health Technology |
- Stock Market
- Insiders
- Aram Andrew Mangasarian